Ads
related to: new antiplatelet drugs for anxiety disorder symptoms and criteria definition
Search results
Results from the WOW.Com Content Network
Vortioxetine was under development for the treatment of generalized anxiety disorder [59] and attention-deficit hyperactivity disorder (ADHD) [60] but development for these indications was discontinued. [61] As of August 2021, vortioxetine remains in development for the treatment of anxiety disorders, binge-eating disorder, and bipolar disorder ...
Major depressive disorder; Generalized anxiety disorder; Social anxiety disorder; Panic disorder; Chronic pain syndromes [20] Vasomotor symptoms of menopause (hot flashes) [21] 1994: The first and most commonly used SNRI. It was introduced by Wyeth in 1994. The reuptake effects of venlafaxine are dose-dependent.
This is a list of investigational social anxiety disorder drugs, or drugs that are currently under development for clinical use in the treatment of social anxiety disorder (SAD; or social phobia) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
This is a list of investigational anxiolytics, or anxiolytics that are currently under development for clinical use but are not yet approved.Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Antiplatelet therapy with one or more of these drugs decreases the ability of blood clots to form by interfering with the platelet activation process in primary hemostasis. Antiplatelet drugs can reversibly or irreversibly inhibit the process involved in platelet activation resulting in decreased tendency of platelets to adhere to one another ...
Anxiety is a naturally-occurring emotion and response. When anxiety levels exceed the tolerability of a person, anxiety disorders may occur. People with anxiety disorders can exhibit fear responses, such as defensive behaviors, high levels of alertness, and negative emotions.
Ads
related to: new antiplatelet drugs for anxiety disorder symptoms and criteria definition